Text Size

Determinants of Compliance With Glaucoma Therapy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Steven L. Mansberger, Legacy Health System
ClinicalTrials.gov Identifier:
NCT01484392
First received: November 30, 2011
Last updated: December 1, 2011
Last verified: November 2011
History of Changes
  Purpose

The purpose of this study is to determine which medical, demographic, and health belief factors are associated with glaucoma therapy compliance.


Condition
Open Angle Glaucoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Determinants of Compliance With Glaucoma Therapy

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Further study details as provided by Legacy Health System:

Primary Outcome Measures:
  • Compliance with glaucoma medication at 1 month [ Time Frame: 1 month after enrollment ] [ Designated as safety issue: No ]
    Compliance is measured using the Travatan Dosing Aid, a device that records when patients administer their topical glaucoma medication.

  • Compliance with glaucoma medication at 3 months [ Time Frame: 3 months after enrollment ] [ Designated as safety issue: No ]
    Compliance is measured using the Travatan Dosing Aid, a device that records when patients administer their topical glaucoma medication.


Enrollment: 60
Study Start Date: August 2006
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients diagnosed with open angle glaucoma.

Criteria

Inclusion Criteria:

  • open angle glaucoma
  • be well controlled on current medical therapy
  • be using a prostaglandin analogue
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01484392

Locations
United States, Oregon
Devers Eye Institute
Portland, Oregon, United States, 97210
Sponsors and Collaborators
Legacy Health System
Investigators
Principal Investigator: Steven L Mansberger, MD, MPH Legacy Health
  More Information

No publications provided

Responsible Party: Steven L. Mansberger, Associate Scientist, Legacy Health System
ClinicalTrials.gov Identifier: NCT01484392     History of Changes
Other Study ID Numbers: FWA00001280
Study First Received: November 30, 2011
Last Updated: December 1, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Legacy Health System:
open angle glaucoma
compliance
adherence

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases

ClinicalTrials.gov processed this record on June 17, 2013